Loading
Genrix Bio is a Shanghai antibody company, listed on the Shanghai STAR market, whose oncology lead GR1803 is a BCMA and CD3 bispecific T-cell engager for multiple myeloma.
Genrix (Shanghai) Biopharmaceutical, a subsidiary of Zhifei Biological Products, develops monoclonal and bispecific antibodies. Its first approved product is the IL-17A antibody xeligekimab for psoriasis; its pipeline spans autoimmune, infectious and cancer indications. GR1803, a bispecific antibody binding BCMA on myeloma cells and CD3 on T cells, is in a phase 1/2 trial in relapsed or refractory multiple myeloma.
GR1803 is an experimental investigational agent whose form is not stated in the registry from Genrix (Shanghai) Biopharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.